Solventum (SOLV) Q2 2026 Earnings Call Transcript

Solventum reported Q2 total net sales of $2.2B (+2.2% reported, +9.5% organic) and adjusted diluted EPS of $2.55 (+50.9% YoY), helped by a $0.48 one-time tariff refund and $144M free cash flow. The company raised full-year 2026 guidance: organic sales growth to 2.5%–3% (from 2%–3%), adjusted EPS to $7.10–$7.20 (from $6.40–$6.60), and free cash flow to $200M–$300M (from ~$200M). Management also announced intent to separate the Health Information Systems (HIS) segment, while noting ERP advanced orders ($125M; $0.34 EPS impact) will reverse in Q3 and keep that period weaker (sales growth expected ~-3% to -4%).

Analysis

The important signal here is not the beat itself; it is that the business is close to clearing a multi-quarter operational overhang. Once the ERP/order-timing distortions and separation costs wash through, SOLV should look less like a complex carve-out and more like a focused medtech compounder with better cash conversion, a cleaner peer set, and a more defensible multiple. That said, the market will have to underwrite a near-term air pocket first: management has effectively telegraphed a weak sequential quarter, which creates a very real sell-the-news risk over the next 4-8 weeks.

Strategically, the HIS separation is the bigger story than the quarterly upside. HIS is high-margin and resilient, so removing it can create an EPS gap, but it also sharpens the remaining growth narrative and may unlock a higher EV/EBIT multiple if investors stop discounting separation complexity. The second-order effect is that cash deployment becomes more visible: if proceeds are real, buybacks and debt paydown could matter more than headline revenue growth for the next 12 months. The main falsifier is simple: if normalized organic growth cannot hold in the 3.5%-4% ex-SKU range after the ERP noise clears, or if margins slip once tariff/refund benefits roll off, the re-rating thesis breaks.

Contrarian take: consensus may be too focused on the Q2 optics and not enough on the structural reset. The company is not becoming a faster grower next quarter; it is becoming a higher-quality one over 6-18 months. If the stock sells off on the Q3 reset, that may be the better entry point than chasing the current print.

Key Decisions for Investors

• Buy SOLV on post-earnings weakness over the next 2-4 weeks; frame as a 6-12 month re-rating trade tied to post-ERP normalization and cash-flow inflection.
• If long SOLV now, hedge the Q3 reset with short-dated puts or a put spread into the quarter where management already flagged negative reported growth; the goal is to protect against the known timing reversal.
• Pair trade: long SOLV / short MMM for 3-6 months as a cleaner portfolio-simplification and margin-recovery story versus a more complex transformation path elsewhere in medtech-related names.
• Add only if Q3 confirms the bridge: look for normalized organic growth back to positive low-single digits and operating margin holding above ~22% excluding one-time items; if not, cut exposure.
• Watch the HIS process as a catalyst alert, not a standalone thesis driver: if separation terms imply meaningful proceeds and limited stranded cost, that is the signal to add on the next pullback.